Monday May 6, 2024 | Last Update: May 6, 2024 EDT
From just being another generics drug maker the past five years, Actavis has earned a spot in one of the Top 10 pharmaceutical companies in the world by market value—thanks to its strategic dealmaking with the $66 billion acquisition of Allergan, Inc.
Read more >>
Actavis is trying its best to finish the deal with Allergan and plans to pay more than $210 per share, or over $62 billion for the pharmaceutical company—higher than their previous offer.
Actavis plans to buy another pharmaceutical company, botox maker Allergan Inc. for at least $60 Billion in order to escape Valeant Pharmaceuticals International Inc.’s hostile offer.
Just In
Most Read
1
2
3
4
5
